Leukemia Research
Volume 26, Issue 10 , Pages 893-897 , October 2002

Treatment of myelodysplastic syndromes with 5-azacytidine

  • Jeffrey Gryn

      Affiliations

    • Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-412-578-1605; fax: +1-412-578-4391
    • ,
  • Zella R. Zeigler

      Affiliations

    • Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA
    • ,
  • Richard K. Shadduck

      Affiliations

    • Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA
    • ,
  • John Lister

      Affiliations

    • Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA
    • ,
  • Jane M. Raymond

      Affiliations

    • Western Pennsylvania Cancer Institute, 4800 Friendship Avenue, Suite 2303, Pittsburgh, PA 15224, USA
    • ,
  • Ibrahim Sbeitan

      Affiliations

    • Hematology/Oncology, 1086 Franklin Street, Johnstown, PA 15905, USA
    • ,
  • Charles Srodes

      Affiliations

    • Medical Center Clinic, 5200 Centre Avenue, Suite 706, Pittsburgh, PA 15232, USA
    • ,
  • Dennis Meisner

      Affiliations

    • Medical Center Clinic, 5200 Centre Avenue, Suite 706, Pittsburgh, PA 15232, USA
    • ,
  • Cynthia Evans

      Affiliations

    • Medical Center Clinic, 5200 Centre Avenue, Suite 706, Pittsburgh, PA 15232, USA

Received 5 November 2001 ,Accepted 28 January 2002.

References 

  1. Anderson JE, Appelbaum FR, Fisher LD, et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677–681
  2. Greenberg P, Cox C, Le Beau MM, et al.  International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  3. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68–75
  4. Koeffler HP, Hirji K, Itri L. Randomized study of 13-cis-retinoic acid vs. placebo in the myelodysplastic disorders. Blood. 1988;71:703–708
  5. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann. Hematol. 1992;65:162–168
  6. Beran M, Estey E, O’Brien SM, et al.  Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Lymphoma. 1998;31:521–531
  7. Creusot F, Acs G, Christman J. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-AZA-2′-deoxycytidine. J. Biol. Chem. 1982;257:2041–2048
  8. Christman J, Price P, Pedrinan L, Acs G. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur. J. Biochem. 1977;81:53–61
  9. Silverman LR, Holland JF, Weinberg RS, et al.  Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl. 1):21–29
  10. Silverman LR, Holland JF, Davis RB, et al.  Azacytidine induces trilineage responses in patients with myelodysplastic syndromes: the Cancer and Leukemia Group B experience. Hematologica. 1991;76:42
  11. Silverman L, Demakos E, Peterson B, et al.  A randomized controlled trial of subcutaneous azacytidine (AZA C) in patients with the myelodysplastic syndrome (MDS): a study of the CALGB. Proc. Am. Soc. Clin. Oncol. 1998;17:14a
  12. Cheson BD, Bennett JM, Kantarjian H, et al.  Report of an International Working Group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  13. Wijermans PW, Luebbert M, Verhoef GEG. Low dose decitabine in elderly patients with high risk MDS. Who will respond best? In: Proceedings of the Sixth International Symposium on Myelodysplastic Syndromes. Stockholm, Sweden, June 2001.
  14. Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk. Lymphoma. 1999;35:437–443

PII: S0145-2126(02)00028-0

Leukemia Research
Volume 26, Issue 10 , Pages 893-897 , October 2002

Article Tools